Your browser is no longer supported. Please, upgrade your browser.
RAPT RAPT Therapeutics, Inc. daily Stock Chart
RAPT Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.63 Insider Own1.00% Shs Outstand16.86M Perf Week59.35%
Market Cap330.46M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-
Income-37.10M PEG- EPS next Q- Inst Own62.00% Short Float- Perf Quarter-
Sales- P/S- EPS this Y-24.20% Inst Trans- Short Ratio- Perf Half Y-
Book/sh-142.11 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.67 P/C5.35 EPS next 5Y- ROE- 52W Range11.85 - 42.00 Perf YTD50.77%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-53.33% Beta-
Dividend %- Quick Ratio18.20 Sales past 5Y- Gross Margin- 52W Low65.40% ATR5.69
Employees62 Current Ratio18.20 Sales Q/Q- Oper. Margin- RSI (14)- Volatility42.93% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.77 Prev Close28.10
ShortableNo LT Debt/Eq- Earnings- Payout- Avg Volume161.18K Price19.60
Recom- SMA2016.41% SMA5016.41% SMA20016.41% Volume123,499 Change-30.25%
Nov-11-19 10:56AM  Weekly CEO Buys Highlight -30.25%
Oct-30-19 08:49PM  RAPT Therapeutics Announces Pricing of Initial Public Offering Business Wire
Jul-30-19 03:25PM  Rapt Therapeutics IPO: What You Need To Know Benzinga
Jul-28-19 02:08PM  IPO Outlook For The Week: Cannabis, Cancer Therapy, Sushi And Holographic AR Benzinga
RAPT Therapeutics, Inc., a clinical stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company develops small molecules that are designed to modulate the critical immune responses underlying these diseases. Its lead oncology drug candidate is FLX475 for the treatment of a range of tumors; and RPT193, a CCR4 antagonist for allergic inflammatory disease. The company is also pursuing a range of targets, including general control nonderepressible and hematopoietic progenitor kinase for the treatment of cancer. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.